Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica.
Abstract
Dissertation presented to obtain the Ph.D degree in Engineering and Technology Sciences-BiotechnologyBiopharmaceuticals derived from recombinant viruses comprise a plethora of
prophylactic and therapeutic products from vaccines to gene therapy vectors.
Retroviruses occupy an important segment of this market. Replication-defective
vectors have extensively been used as delivery vehicles in gene therapy protocols.
Retrovirus-like-particles have shown promising results in vaccinology as immunogen
display platforms. Replication-competent particles have efficiently been used as
oncolytic agents. (...
